Epigenetics and blood disorders

No abstract is available for this paper.

• Publication year

  2012

• Venue

  British Journal of Haematology

• Publication date

  2012-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1365-2141.2012.09193.xPMID 22712628
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells.

  2012cited by this paper
• Active DNA demethylation by Gadd45 and DNA repair.

  2012cited by this paper
• Cross-talk between DNA methylation and active histone modifications regulates aberrant expression of ZAP70 in CLL

  2012cited by this paper
• Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT

  2012cited by this paper
• Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia.

  2012cited by this paper
• The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage.

  2012cited by this paper
• Rapid Synthesis of New DNMT Inhibitors Derivatives of Procainamide

  2012cited by this paper
• The same pocket in menin binds both MLL and JUND but has opposite effects on transcription

  2012cited by this paper
• Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).

  2012cited by this paper
• Dnmt3a is essential for hematopoietic stem cell differentiation

  2011cited by this paper
• The Mutational Landscape of Head and Neck Squamous Cell Carcinoma

  2011cited by this paper
• Evolving Insights in the Pathogenesis and Therapy of Cutaneous T‐cell lymphoma (Mycosis Fungoides and Sezary Syndrome)

  2011cited by this paper
• The heterodimerization domains of MLL—FYRN and FYRC—are potential target structures in t(4;11) leukemia

  2011cited by this paper
• Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia

  2011cited by this paper
• The Genetic Landscape of the Childhood Cancer Medulloblastoma

  2011cited by this paper
• R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1α upregulation in adult glioma

  2011cited by this paper
• Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

  2011cited by this paper
• Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation.

  2011cited by this paper
• Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA

  2011cited by this paper
• Development of an Oral Form of Azacytidine: 2′3′5′Triacetyl-5-Azacytidine

  2011cited by this paper
• Structure and Function of Mammalian DNA Methyltransferases

  2011cited by this paper
• Recurrent DNMT3A Mutations in Patients with Myelodysplastic Syndromes

  2011cited by this paper
• Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells.

  2011cited by this paper
• HIstome—a relational knowledgebase of human histone proteins and histone modifying enzymes

  2011cited by this paper
• The leukemogenic AF4–MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures

  2011cited by this paper
• Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL.

  2011cited by this paper
• Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.

  2011cited by this paper
• Mechanisms of leukemogenesis by MLL fusion proteins

  2011cited by this paper
• Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

  2011cited by this paper
• Experience with use of Zostavax® in patients with hematologic malignancy and hematopoietic cell transplant recipients

  2011cited by this paper
• Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies.

  2011cited by this paper
• Regulation of chromatin by histone modifications

  2011cited by this paper
• Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.

  2011cited by this paper
• Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia

  2011cited by this paper
• Epigenomics in hematopoietic transplantation: novel treatment strategies.

  2011cited by this paper
• Biological functions of methyl-CpG-binding proteins.

  2011cited by this paper
• Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies.

  2011cited by this paper
• The oncometabolite 2‐hydroxyglutarate inhibits histone lysine demethylases

  2011cited by this paper
• Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice.

  2010cited by this paper
• Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes.

  2010cited by this paper
• S110, a 5-Aza-2′-Deoxycytidine–Containing Dinucleotide, Is an Effective DNA Methylation Inhibitor In vivo and Can Reduce Tumor Growth

  2010cited by this paper
• The epigenomic interface between genome and environment in common complex diseases.

  2010cited by this paper
• Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms.

  2010cited by this paper
• DNMT3A mutations in acute myeloid leukemia.

  2010cited by this paper
• Binding of the MLL PHD3 finger to histone H3K4me3 is required for MLL-dependent gene transcription.

  2010cited by this paper
• The patterns and dynamics of genomic instability in metastatic pancreatic cancer

  2010cited by this paper
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2010cited by this paper
• Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

  2010cited by this paper
• Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome

  2010cited by this paper
• Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

  2010cited by this paper
• Nonhistone protein acetylation as cancer therapy targets

  2010cited by this paper
• The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

  2010cited by this paper
• A pilot study of the Histone‐Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms

  2010cited by this paper
• The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4.

  2010cited by this paper
• Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact

  2010cited by this paper
• Expression of multidrug resistance-associated ABC transporters in B-CLL is independent of ZAP70 status

  2010cited by this paper
• Histone H4 acetylation by immunohistochemistry and prognosis in newly diagnosed adult acute lymphoblastic leukemia (ALL) patients

  2010cited by this paper
• Reversal of histone methylation: biochemical and molecular mechanisms of histone demethylases.

  2010cited by this paper
• Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non‐Hodgkin lymphoma: dose‐limiting myelosuppression without evidence of DNA hypomethylation

  2010cited by this paper
• Romidepsin for the treatment of cutaneous T-cell lymphoma.

  2009cited by this paper
• Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

  2009cited by this paper
• The molecular biology of mixed lineage leukemia

  2009cited by this paper
• IDH 1 and IDH 2 Mutations in Gliomas

  2009cited by this paper
• Mutation in TET2 in myeloid cancers.

  2009cited by this paper
• Epigenetic Cross-Talk between DNA Methylation and Histone Modifications in Human Cancers

  2009cited by this paper
• Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma

  2009cited by this paper
• Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α

  2009cited by this paper
• Histone Deacetylase Inhibitors Induce a Very Broad, Pleiotropic Anticancer Drug Resistance Phenotype in Acute Myeloid Leukemia Cells by Modulation of Multiple ABC Transporter Genes

  2009cited by this paper
• A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation.

  2009cited by this paper
• Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases.

  2009cited by this paper
• DNA excision repair proteins and Gadd45 as molecular players for active DNA demethylation

  2009cited by this paper
• Recurring mutations found by sequencing an acute myeloid leukemia genome.

  2009cited by this paper
• IDH1 and IDH2 mutations in gliomas.

  2009cited by this paper
• Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

  2009cited by this paper
• New insights to the MLL recombinome of acute leukemias

  2009cited by this paper
• IDH1 and IDH2 mutations in gliomas.

  2009cited by this paper
• Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions

  2009cited by this paper
• Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms.

  2009cited by this paper
• Faculty Opinions recommendation of Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.

  2009cited by this paper
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2009cited by this paper
• Menin critically links MLL proteins with LEDGF on cancer-associated target genes.

  2008cited by this paper
• Genomewide Analysis of PRC1 and PRC2 Occupancy Identifies Two Classes of Bivalent Domains

  2008cited by this paper
• Clinical Trials and Observations

  2008cited by this paper
• An Integrated Genomic Analysis of Human Glioblastoma Multiforme

  2008cited by this paper
• Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine

  2008cited by this paper
• Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

  2008cited by this paper
• Epigenetic regulation of gene expression in the inflammatory response and relevance to common diseases.

  2008cited by this paper
• Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.

  2008cited by this paper
• H3K79 methylation profiles define murine and human MLL-AF4 leukemias.

  2008cited by this paper
• Expanding chemical biology of 2-oxoglutarate oxygenases.

  2008cited by this paper
• Reduction of B cell turnover in chronic lymphocytic leukaemia

  2008cited by this paper
• Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells.

  2008cited by this paper
• Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes

  2008cited by this paper
• The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling.

  2007cited by this paper
• Cancer epigenomics: DNA methylomes and histone-modification maps

  2007cited by this paper
• Phase II study of low‐dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia

  2007cited by this paper
• Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.

  2007cited by this paper
• Depsipeptide (FK228) Preferentially Induces Apoptosis in BCR/ABL-Expressing Cell Lines and Cells from Patients with Chronic Myelogenous Leukemia in Blast Crisis

  2007cited by this paper
• Gene silencing by DNA methylation in haematological malignancies

  2007cited by this paper
• MLL translocations, histone modifications and leukaemia stem-cell development

  2007cited by this paper

• Molecular pathological approach to cancer epigenomics and its clinical application

  2024cites this paper
• Elucidating the Importance of DOT1L Recruitment in MLL-AF9 Leukemia and Hematopoiesis

  2021cites this paper
• toxicant induced epigenetic transgenerational inheritance of ovarian pathology and granulosa cell epigenome and transcriptome alterations: ancestral origins of polycystic ovarian syndrome and primary ovarian insufiency. Epigenetics. 2018;13(8):875-895

  2019cites this paper
• Inter-Strain Differences in LINE-1 DNA Methylation in the Mouse Hematopoietic System in Response to Exposure to Ionizing Radiation

  2017cites this paper
• Study of the Epigenetic Signals in the Human Genome

  2017cites this paper
• MLL-r Leukemia

  2016cites this paper
• The mechanistic role of epigenetic in multiple myeloma

  2016influential citation
• Exposure to Low-Dose 56Fe-Ion Radiation Induces Long-Term Epigenetic Alterations in Mouse Bone Marrow Hematopoietic Progenitor and Stem Cells

  2014cites this paper
• The study of epigenetic mechanisms based on the analysis of histone modification patterns by flow cytoametry

  2014cites this paper
• Inhibition of class I HDACs abrogates the dominant effect of MLL-AF4 by activation of wild-type MLL

  2014cites this paper
• Role of Epigenetics in Chronic Myeloid Leukemia

  2013cites this paper
• Epigenetic regulation of cell signaling pathways in acute lymphoblastic leukemia.

  2013cites this paper
• Epigenetic regulation of micrornas in prostate cancer

  2012influential citation